BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 16583431)

  • 1. Thalidomide therapy for myelofibrosis with myeloid metaplasia.
    Thomas DA; Giles FJ; Albitar M; Cortes JE; Verstovsek S; Faderl S; O'Brien SM; Garcia-Manero G; Keating MJ; Pierce S; Zeldis J; Kantarjian HM
    Cancer; 2006 May; 106(9):1974-84. PubMed ID: 16583431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.
    Marchetti M; Barosi G; Balestri F; Viarengo G; Gentili S; Barulli S; Demory JL; Ilariucci F; Volpe A; Bordessoule D; Grossi A; Le Bousse-Kerdiles MC; Caenazzo A; Pecci A; Falcone A; Broccia G; Bendotti C; Bauduer F; Buccisano F; Dupriez B
    J Clin Oncol; 2004 Feb; 22(3):424-31. PubMed ID: 14752066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study.
    Piccaluga PP; Visani G; Pileri SA; Ascani S; Grafone T; Isidori A; Malagola M; Finelli C; Martinelli G; Ricci P; Baccarani M; Tura S
    Leukemia; 2002 Sep; 16(9):1609-14. PubMed ID: 12200671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.
    Daliani DD; Papandreou CN; Thall PF; Wang X; Perez C; Oliva R; Pagliaro L; Amato R
    Cancer; 2002 Aug; 95(4):758-65. PubMed ID: 12209719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
    Mita MM; Rowinsky EK; Forero L; Eckhart SG; Izbicka E; Weiss GR; Beeram M; Mita AC; de Bono JS; Tolcher AW; Hammond LA; Simmons P; Berg K; Takimoto C; Patnaik A
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):165-74. PubMed ID: 16736151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalidomide for the treatment of idiopathic myelofibrosis.
    Strupp C; Germing U; Scherer A; Kündgen A; Mödder U; Gattermann N; Haas R
    Eur J Haematol; 2004 Jan; 72(1):52-7. PubMed ID: 14962263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.
    Figg WD; Dahut W; Duray P; Hamilton M; Tompkins A; Steinberg SM; Jones E; Premkumar A; Linehan WM; Floeter MK; Chen CC; Dixon S; Kohler DR; Krüger EA; Gubish E; Pluda JM; Reed E
    Clin Cancer Res; 2001 Jul; 7(7):1888-93. PubMed ID: 11448901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
    McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
    Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study.
    Abgrall JF; Guibaud I; Bastie JN; Flesch M; Rossi JF; Lacotte-Thierry L; Boyer F; Casassus P; Slama B; Berthou C; Rodon P; Leporrier M; Villemagne B; Himberlin C; Ghomari K; Larosa F; Rollot F; Dugay J; Allard C; Maigre M; Isnard F; Zerbib R; Cauvin JM;
    Haematologica; 2006 Aug; 91(8):1027-32. PubMed ID: 16885042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma.
    Lin AY; Brophy N; Fisher GA; So S; Biggs C; Yock TI; Levitt L
    Cancer; 2005 Jan; 103(1):119-25. PubMed ID: 15565573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
    Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
    Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer.
    Eisen T; Boshoff C; Mak I; Sapunar F; Vaughan MM; Pyle L; Johnston SR; Ahern R; Smith IE; Gore ME
    Br J Cancer; 2000 Feb; 82(4):812-7. PubMed ID: 10732751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
    Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
    Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial.
    Moreno-Aspitia A; Colon-Otero G; Hoering A; Tefferi A; Niedringhaus RD; Vukov A; Li CY; Menke DM; Geyer SM; Alberts SR;
    Cancer; 2006 Aug; 107(4):767-72. PubMed ID: 16826578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies.
    Bouscary D; Legros L; Tulliez M; Dubois S; Mahe B; Beyne-Rauzy O; Quarre MC; Vassilief D; Varet B; Aouba A; Gardembas M; Giraudier S; Guerci A; Rousselot P; Gaillard F; Moreau A; Rousselet MC; Ifrah N; Fenaux P; Dreyfus F;
    Br J Haematol; 2005 Dec; 131(5):609-18. PubMed ID: 16351636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
    Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
    Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens.
    Thapaliya P; Tefferi A; Pardanani A; Steensma DP; Camoriano J; Wu W; Geyer S; Mesa RA
    Am J Hematol; 2011 Jan; 86(1):96-8. PubMed ID: 21132732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies.
    Gilheeney SW; Lyden DC; Sgouros S; Antunes N; Gerald W; Kramer K; Lis E; Meyers P; Rosen N; Thaler HT; Trippett T; Wexler L; Dunkel IJ
    Pediatr Blood Cancer; 2007 Sep; 49(3):261-5. PubMed ID: 16972243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
    Rajkumar SV; Witzig TE
    Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of lenalidomide in myelodysplastic syndromes.
    List A; Kurtin S; Roe DJ; Buresh A; Mahadevan D; Fuchs D; Rimsza L; Heaton R; Knight R; Zeldis JB
    N Engl J Med; 2005 Feb; 352(6):549-57. PubMed ID: 15703420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.